Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33290-33305

  Rao, Chinthalapally V ^a   Janakiram, Naveena B ^a   Madka, Venkateshwar ^a   Devarkonda, Vishal ^a   Brewer, Misty ^a   Biddick, Laura ^a   Lightfoot, Stan ^a   Steele, Vernon E ^b   Mohammed, Altaf ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Chemoprevention; EGFR; Inflammation; Pancreatic cancer

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; BETA CATENIN; CYCLINE; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELATINASE B; LICOFELONE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 17; MATRIX METALLOPROTEINASE 19; MATRIX METALLOPROTEINASE 23; MATRIX METALLOPROTEINASE 28; PROTEIN P21; STROMELYSIN; STROMELYSIN 3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; EGFR PROTEIN, MOUSE; LIPOXYGENASE INHIBITOR; PYRROLE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INCIDENCE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; MALE; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONATE 5-LIPOXYGENASE; CARCINOMA, PANCREATIC DUCTAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DRUG SYNERGISM; FEMALE; LIPOXYGENASE INHIBITORS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PANCREATIC NEOPLASMS; PYRROLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84946013192     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5396     Document Type: Article

References (40)

1. American Cancer Society 2015. Cancer facts and figures. 2015; Atlanta, GA.
2. Rao CV, Mohammed A, Janakiram NB, Qian L, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE. Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48Cre/+-LSL-KrasG12D/+ Mice. Neoplasia. 2012; 14:778-787.
3. Funahashi H, Satake M, Dawson D, Huynh NA, Reber HA, Hines OJ, Eibl G. Delayed progression of pancreatic intraepithelial neoplasia in a conditional Kras(G12D) mouse model by a selective cyclooxygenase-2 inhibitor. Cancer Res. 2007; 67:7068-7071.
4. Silvia D. Stan, Shivendra V. Singh, Randall E. Brand. Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2010; 7:347-356.
5. Mohammed A, Janakiram NB, Madka V, Brewer M, Ritchie RL, Lightfoot S, Kumar G, Sadeghi M, Patlolla JM, Yamada HY, Cruz-Monserrate Z, May R, Houchen CW, et al. Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget. 2015; 6:15524-15539.
6. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E. Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005; 352:1071-1080.
7. Arber N, Eagle CJ, Spicak J, Rácz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006; 355:885-895.
8. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim KM, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, et al. Five-year efficacy and safety analysis of the Adenoma Prevention with Celecoxib Trial. Cancer Prev Res. 2009; 2:285-287.
9. Duffield-Lillico AJ, Boyle JO, Zhou XK, Ghosh A, Butala GS, Subbaramaiah K, Newman RA, Morrow JD, Milne GL, Dannenberg AJ. Levels of prostaglandin E metabolite and leukotriene E4 are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway. Cancer Prev Res. 2009; 2:322-329.
10. Bergmann F, Moldenhauer G, Herpel E, Gaida MM, Strobel O, Werner J, Esposito I, Müerköster SS, Schirmacher P, Kern MA. Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets? Histopathology. 2010; 56:440-448.
11. Mohammed A, Janakiram NB, Lightfoot S, Gali H, Vibhudutta A, Rao CV. Early Detection and Prevention of Pancreatic Cancer: Use of Genetically Engineered Mouse Models and advanced Imaging Technologies. Cur Med Chem. 2012; 19:3701-3713.
12. Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfot S, Crawford H, Steele VE, Rao CV. The Epidermal Growth Factor Receptor Inhibitor Gefitinib Prevents the Progression of Pancreatic Lesions to Carcinoma in a Conditional LSL-KrasG12D/+ Transgenic Mouse Model. Cancer Prev Res. 2010; 11:1417-1426.
13. Mohammed A, Qian L, Janakiram NB, Lightfoot S, Steele VE, Rao CV. Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/1 LSL-KrasG12D/1 mice. Int J Cancer. 2012; 131:1951-1962.
14. Mohammed A, Janakiram NB, Brewer M, DuffA, Lightfoot S, Brush RS, Anderson RE, Rao CV. Endogenous n-3 Polyunsaturated Fatty Acids delay progression of Pancreatic Ductal Adenocarcinoma in Fat-1.P48Cre/+-LSLKrasG12D/+ mice. Neoplasia. 2012; 14:1249-1259.
15. Rao CV, Mohammed A, Janakiram NB, Qian L, Ritchie RL, Lightfoot S, Vibhudutta A, Steele VE. Inhibition of Pancreatic Intraepithelial Neoplasia Progression to Carcinoma by Nitric Oxide-Releasing Aspirin in p48Cre/+-LSL-KrasG12D/+ Mice. Neoplasia. 2012; 14:778-787.
16. Hocker JR, Mohammed A, Aston CE, Brewer M, Lightfoot SA, Rao CV, Hanas JS. Mass Profiling of Serum to Distinguish Mice with Pancreatic Cancer Induced by a Transgenic Kras Mutation. Int J Cancer. 2013; 133:2662-2671.
17. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV. Antidiabetic Drug Metformin Prevents Progression of Pancreatic Cancer by Targeting in Part Cancer Stem Cells and mTOR Signaling. Transl Oncol. 2013; 6:649-659.
18. Mohammed A, Janakiram NB, Madka V, Ritchie RL, Brewer M, Biddick L, Patlolla JM, Sadeghi M, Lightfoot S, Steele VE, Rao CV. Eflornithine (DFMO) Prevents Progression of Pancreatic Cancer by Modulating Ornithine Decarboxylase Signaling. Cancer Prev Res. 2014; 7:1198-1209.
19. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, TarassoffP, Nelson R, Dorr FA, Stephens CD, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15:2403-2413.
20. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, WolffRA, Campos D, Lim R, Ding K, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25:1960-1966.
21. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von HoffDD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21:418-429.
22. Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, Ewska JC. Expression of EGF and EGFR Strongly Correlates with Metastasis of Pancreatic Ductal Carcinoma. Anticancer Res. 2004; 28:1399-1404.
23. Durkin AJ, Bloomston PM, Rosemurgy AS, Giarelli N, Cojita D, Yeatman TJ, Zervos EE. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg. 2003; 186:431-436.
24. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest. 1992; 90:1352-1360.
25. Elder DJ, Halton DE, Playle LC, Paraskeva C. The MEK/ERK pathway mediates COX-2-selective NSAIDinduced apoptosis and induced COX-2 protein expression in colorectal carcinoma cells. Int J Cancer. 2002; 99:323-327.
26. Sheng H, Shao J, DuBois RN. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells. J Biol Chem. 2001; 276:14498-14504.
27. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002; 8:289-293.
28. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta. 1999; 1438:120-130.
29. El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2-dependent and-independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther. 2004; 3:1421-6.
30. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem. 2002; 277:27613-27621.
31. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, Shaw YJ, Kulp SK, Chen CS. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res. 2004; 64:4309-4318.
32. Mohammed A, Janakiram NB, Li Q, Choi CI, Zhang Y, Steele VE, Rao CV. Chemoprevention of colon and small intestinal tumorigenesis in APC(Min/+) mice by licofelone, a novel dual 5-LOX/COX inhibitor: potential implications for human colon cancer prevention. Cancer Prev Res. 2011; 4:2015-2026.
33. Madka V, Mohammed A, Li Q, Zhang Y, Patlolla JM, Biddick L, Lightfoot S, Wu XR, Steele V, Kopelovich L, Rao CV. Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice. Cancer Prev Res. 2014; 7:708-716.
34. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, Shin DM. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004; 10:5930-5939.
35. Tortora G, Caputo R, Damiano V, Melisi D, Bianco R, Fontanini G, Veneziani BM, De Placido S, Bianco AR, Ciardiello F. Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect. Clin Cancer Res. 2003; 9:1566-1572.
36. Half E, Freeburg E, Sun Y, Sinicrope F. EGFR and HER-2 receptor blockade attenuate cyclooxygenase-2 expression and augment NSAID-mediated apoptosis in human colon cancer cells. In: Miami: ASCO GI Cancer Symposium. 2005.
37. Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther. 2005; 4:1943-1951.
38. Roos J, Oancea C, Heinssmann M, Khan D, Held H, Kahnt AS, Capelo R, la Buscató E, Proschak E, Puccetti E, Steinhilber D, Fleming I, Maier TJ, et al. 5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia. Cancer Res. 2014; 74:5244-5255.
39. Bao B, Wang Z, Ali S, Ahmad A, Azmi AS, Sarkar SH, Banerjee S, Kong D, Li Y, Thakur S, Sarkar FH. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res. 2012; 5:355-364.
40. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009; 69:7507-7511.